A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Inclusion Criteria:

• Age range from 18 to 75 years old (including boundary values), regardless of gender.

• The clinical diagnosis of enrolled participants should meet the following criteria:

1. Dose escalation and dose expansion stage: Patients with locally advanced ormetastatic solid tumors confirmed by histology or cytology and judged by theresearcher to be unable to benefit from available standard treatment, orintolerant.

2. Indications expansion stage:

• Queue 1: Non-small cell lung cancer (NSCLC) confirmed by histology orcytology, with disease progression and EGFR mutation during or aftertreatment with third generation TKI and platinum containing therapy.

• Queue 2: Breast cancer (BC) confirmed as HER3 positive by histology orcytology after standard treatment failure.

• Queue 3: Patients with recurrent/metastatic advanced HNSCC confirmed byhistology or cytology, unsuitable for radical surgical resection, andstandard treatment failure.

• At least one measurable lesion must be selected as the target lesion (according toRECIST v1.1 standard, computed tomography (CT) or magnetic resonance imaging (MRI)) (for lesions that have previously received radiotherapy, only with clear progressioncan they be selected as the target lesion).

• The patient has not previously used anti-HER3 antibodies or other HER3 targetedtreatments (such as Deparezumab (HER3-DXd).

• Drugs that have not received any form of topoisomerase I inhibitor in the past,including antibody drug conjugates (ADCs) .

• ECOG score 0-1.

• Expected survival time ≥ 3 months.

• During the screening period, the main organ functions were basically normal (nomedical support such as blood transfusion, granulocyte colony-stimulating factor (G-CSF), or other medical support was received within 14 days before the use of theinvestigational drug):

Blood routine: Absolute value of neutrophils (NE #) ≥ 1.5 × 10 9/L, platelet (PLT) count ≥ 90 × 10 9/L, hemoglobin (HGB) ≥ 90 g/L.

• Women of childbearing age during the screening period who have a negative bloodpregnancy test and are capable of reproduction (including male participants) have nopregnancy plan and voluntarily take effective contraceptive measures during thetrial period and within 6 months after the last dose.

• Voluntarily participate in this study and sign an informed consent form.

Exclusion Criteria:

• Participants with the following tumors:

• The participant has had other malignant tumors that have not been cured withinthe past 5 years (excluding malignant tumors that have been clearly cured, suchas thyroid cancer, cured basal cell carcinoma of the skin, and cervicalcarcinoma in situ).

• The participant has untreated imaging confirmed central nervous systemmetastasis.

• Meningeal metastases.

• Patients with brain metastases who have received systematic or curative brainmetastasis treatment (radiotherapy or surgery) in the past, have been confirmedstable by imaging for at least 4 weeks, and have stopped systemic hormone,antiepileptic, convulsive drugs, and other treatments for more than 2 weekswithout clinical symptoms can be enrolled.

• Participants with a history of previous treatment or surgery, or those who receivedthe following anti-tumor treatments during the planned trial period:

• Patients who accepted the instructions clearly containing traditional Chinesepatent medicines and simple preparations with anti-tumor effect within 2 weeksbefore the first administration;

• Patients undergoing adjuvant therapy within 6 months after surgery;

• Patients who have not recovered from the toxicity of the previous anti-tumortreatment to normal or ≤ level 1 (excluding hair loss);

• Patients who have undergone major surgery, radiation therapy, biologicaltherapy, or chemotherapy within 4 weeks prior to their first administration, orwho have received systemic treatment such as unhealed surgical wounds, ulcersor fractures, or other clinical trial drugs.

• Patients who plan to receive any other anti-tumor treatment (chemotherapy,radiation therapy, immunotherapy, cytokine therapy other than erythropoietin)during the trial period should be excluded (excluding testosterone loweringtherapy for prostate cancer patients).

• The dose (prednisone>10 mg/d or equivalent) at which immunosuppressive effectsare achieved by receiving immunosuppressive agents or systemic corticosteroidswithin one week prior to the use of the investigational drug.

• Participants with a history of previous illnesses or laboratory tests that show thefollowing abnormalities:

• Individuals with abnormal coagulation function and a tendency to bleed, or whoare undergoing thrombolysis or anticoagulation treatment or have lost blood ordonated more than 400 mL within 2 months prior to administration.

• Have a history of immunodeficiency, including HIV testing positive, or otheracquired or congenital immunodeficiency diseases, or a history of organtransplantation.

• Have a clear history of neurological or psychiatric disorders, includingepilepsy or dementia.

• Screening period for syphilis spiral antibody positive individuals; Individuals withactive HBV and HCV infections; Except those with stable hepatitis B (DNA titer belowthe lower detection limit) and cured hepatitis C (HCV RNA test negative) after drugtreatment.

• Patients with ascites, pleural effusion, and pericardial effusion accompanied byclinical symptoms during the screening period who require drainage, or those whohave undergone serous cavity drainage within 4 weeks before the firstadministration.

• The screening period is accompanied by severe, progressive, or uncontrollablediseases, and the researcher's evaluation determines that the participation of theparticipants in the study will increase the risk. Including but not limited to:

• Cerebrovascular accidents or transient ischemic attacks (within the first 6months of screening); Suffering from heart disease judged by the researcher asunsuitable for participation in this trial, with a severity of cardiac or renaldysfunction ≥ Level II.

• According to the researcher's judgment, there are accompanying diseases thatmetastasis treatment (radiotherapy or surgery) in the past, have been confirmed
stable by imaging for at least 4 weeks, and have stopped systemic hormone,
antiepileptic, convulsive drugs, and other treatments for more than 2 weeks
without clinical symptoms can be enrolled.
 

• Participants with a history of previous treatment or surgery, or those who received
the following anti-tumor treatments during the planned trial period:
 

• Patients who accepted the instructions clearly containing traditional Chinese
patent medicines and simple preparations with anti-tumor effect within 2 weeks
before the first administration;
 

• Patients undergoing adjuvant therapy within 6 months after surgery;
 

• Patients who have not recovered from the toxicity of the previous anti-tumor
treatment to normal or ≤ level 1 (excluding hair loss);
 

• Patients who have undergone major surgery, radiation therapy, biological
therapy, or chemotherapy within 4 weeks prior to their first administration, or
who have received systemic treatment such as unhealed surgical wounds, ulcers
or fractures, or other clinical trial drugs.
 

• Patients who plan to receive any other anti-tumor treatment (chemotherapy,
radiation therapy, immunotherapy, cytokine therapy other than erythropoietin)
during the trial period should be excluded (excluding testosterone lowering
therapy for prostate cancer patients).
 

• The dose (prednisone>10 mg/d or equivalent) at which immunosuppressive effects
are achieved by receiving immunosuppressive agents or systemic corticosteroids
within one week prior to the use of the investigational drug.
 

• Participants with a history of previous illnesses or laboratory tests that show the
following abnormalities:
 

• Individuals with abnormal coagulation function and a tendency to bleed, or who
are undergoing thrombolysis or anticoagulation treatment or have lost blood or
donated more than 400 mL within 2 months prior to administration.
 

• Have a history of immunodeficiency, including HIV testing positive, or other
acquired or congenital immunodeficiency diseases, or a history of organ
transplantation.
 

• Have a clear history of neurological or psychiatric disorders, including
epilepsy or dementia.
 

• Screening period for syphilis spiral antibody positive individuals; Individuals with
active HBV and HCV infections; Except those with stable hepatitis B (DNA titer below
the lower detection limit) and cured hepatitis C (HCV RNA test negative) after drug
treatment.
 

• Patients with ascites, pleural effusion, and pericardial effusion accompanied by
clinical symptoms during the screening period who require drainage, or those who
have undergone serous cavity drainage within 4 weeks before the first
administration.
 

• The screening period is accompanied by severe, progressive, or uncontrollable
diseases, and the researcher's evaluation determines that the participation of the
participants in the study will increase the risk. Including but not limited to:
 

• Cerebrovascular accidents or transient ischemic attacks (within the first 6
months of screening); Suffering from heart disease judged by the researcher as
unsuitable for participation in this trial, with a severity of cardiac or renal
dysfunction ≥ Level II.
 

• According to the researcher's judgment, there are accompanying diseases that
seriously endanger patient safety or affect patient completion of the study.

1. Hypertension that cannot be controlled clinically.

2. Diabetes with poor drug control.

3. Clinically significant thyroid diseases judged by researchers as unsuitable forinclusion.

4. Serious infections that occurred within 4 weeks prior to initiating researchtreatment.

• Individuals with a history of severe allergies to protein products, Chinese hamsterovary cell (CHO) cell products, and other recombinant human or humanized antibodies,or to the components of the investigational drug.

• Pregnant and lactating women.

• Patients deemed unsuitable for inclusion by researchers.